General
Preferred name
liraglutide
Synonyms
Victoza ()
Liraglutida ()
Liraglutidum ()
NN2211 ()
NNC-90-1170 ()
Saxenda ()
NNC 90-1170 ()
NN-9924 ()
Liraglutide recombinant ()
NN-2211 ()
Liraglutide (rdna origin) ()
NN9924 ()
P&D ID
PD046377
CAS
204656-20-2
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2009
2010
Drug indication
Obesity
Type-2 diabetes
Drug Status
approved
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Liraglutide is a synthetic analog of human GLP-1, with the addition of a palmitic acid moeity which acts to increase the drug's half-life and prolong its activity.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
13
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Natural product-based probes and drugs
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
3748.95
Hydrogen Bond Acceptors
49
Hydrogen Bond Donors
54
Rotatable Bonds
130
Ring Count
6
Aromatic Ring Count
6
cLogP
-10.16
TPSA
1513.76
Fraction CSP3
0.59
Chiral centers
31.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
GLP-1
GLP1R
Indication
weight-loss aid, diabetes mellitus
MOA
GLP receptor agonist
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antidiabetic
Therapeutic Class
Metabolic Disorders
Source data
